Post-ASH 2022 iwAL - ALL

12 January 2023 | Virtual Meeting

Expert-led presentations & discussions on key abstracts in ALL from ASH 2022

The Post-ASH 2022 iwAL Virtual Workshop was held on 11-12 January 2023, with a packed program covering acute myeloid leukemia (AML) on Day 1, and acute lymphoblastic leukemia (ALL) on Day 2. Both days featured a series of short presentations on selected abstracts from the 64th ASH Annual Meeting presented by experts with interactive panel discussions after each session.

MRD and multi-agent chemotherapy Targeted treatments – blinatumomab Targeted treatments – inotuzumab ozogamicin Current clinical updates for CAR-T Clinical strategies for Ph+/like ALL

Session 1: MRD-led treatment outcomes and considerations for multi-agent chemotherapy

Results from the GRAALL-2014 trial

Nicolas Boissel Saint-Louis Hospital, Paris, France

Results from the AALL1931 study

Luke Maese University of Utah Health, Salt Lake City, UT, United States

Panel discussion

Session 2: Targeted treatments in B-cell ALL – blinatumomab

Safety run-in results for the Golden Gate study

Elias Jabbour University of Texas MD Anderson Cancer Center, Houston, TX, United States

A two-cohort comparison within the GRAALL-2014/B study

Nicolas Boissel Saint-Louis Hospital, Paris, France

ECOG-ACTIN-E1910 NCTN clinical trial

Mark Litzow Mayo Clinic, Rochester, MN, United States

Primary endpoint analysis of the Blina-CELL trial

Cyril Salek Institute of Haematology and Blood Transfusion, Prague, Czech Republic

Panel discussion

Session 3: Targeted treatments in B-cell ALL – inotuzumab ozogamicin

Inotuzumab ozogamicin for the treatment of MRD-positive B-cell ALL

Jayastu Senapati The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Addition of INO with hyper-CVAD plus blinatumomab for B-ALL

Nicholas Short The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Panel discussion

Session 4: Current clinical updates for CAR-T in B-ALL

Updated outcomes from the SCHOLAR-3 trial

Bijal Shah H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Safety, efficiency and long-term follow-up of AUTO1

Claire Roddie University College London, London, United Kingdom

CD22-targeted CAR-modified T-cells in children & young adults

Regina Myers Children's Hospital of Philadelphia, Philadelphia, PA, United States

Panel discussion

Session 5: Clinical strategy updates for patients with Ph+/like ALL

Results of the AALL1521 study (NCB18424-269)

Sarah Tasian Children's Hospital of Philadelphia, Philadelphia, PA, United States

Ponatinib and blinatumomab for newly diagnosed patients with Ph+ ALL

Nicholas Short The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Novel salvage therapies for adults with ALL with Ph-like fusions

Ibrahim Aldoss City of Hope, Duarte, CA, United States

Panel discussion

The continued success of the iwAL meeting is in no small part due to the ongoing funding of supporters, allowing a unique opportunity for clinicians to be brought together to facilitate interactive and stimulating debates to help improve patient outcomes.
For more information about supporting future iwAL meetings and activities, please contact us here.

For the latest updates in ALL, visit The ALL Channel

Post-ASH 2022 iwAL - ALL

Post-ASH 2022 iwAL - ALL

Sign-up for our Newsletter!